Jose Gildardo Paredes-Vazquez

Dr. Jose Gildardo Paredes-Vazquez

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
GTGiuseppe Tarantini
Giuseppe Tarantini
GTGilbert H.L. Tang
Gilbert H.L. Tang
TPThomas Pilgrim
Thomas Pilgrim
WKWon-K. Kim
Won-K. Kim
AGAdam Greenbaum
Adam Greenbaum
LFLuca Nai Fovino
Luca Nai Fovino
Lifetime treatment of aortic valve disease is a matter of increasing debate. Although the risks of a second aortic valve intervention are recognized, little attention has been given to the challenges of a third. This study delves into the clinical characteristics, indications, and outcomes of patients undergoing 3 aortic valve interventions. The THIRD (THree aortIc Reinterventions for valve Disease) registry is a retrospective multicenter, international study of patients who underwent a third procedure on the aortic valve, either surgically or transcatheter-based. Patients undergoing 2 aortic procedures during the same hospital admission were excluded. Baseline characteristics, timing, and mode of bioprosthetic failure, sequence of the procedures, and clinical outcomes were adjudicated according to the Valve Academic Research Consortium criteria. A total of 51 patients from 11 centers were enrolled in this study. Median follow-up time was 565 (314-1,560) days. Eighteen patients (35%) underwent surgical aortic valve replacement (SAVR), and 33 of 51 patients (65%) underwent transcatheter aortic valve replacement (TAVR) as the third intervention. Mean age was 69 ± 14 years, 20 of 51 patients (39%) were female. STS score was 5.0% (Q1-Q3: 3.3%-7.0%). In all TAVR cases, the indication for the first intervention was severe aortic stenosis, as was the indication in 31 of 45 (69%) of SAVR cases (33% bicuspid). The most prevalent procedure sequence was SAVR-SAVR-TAVR (19/51, 37%), followed by SAVR-SAVR-SAVR (10/51, 20%) and SAVR-TAVR-TAVR (10/51, 20%). TAVR-TAVR-TAVR was performed in 4 of 51 cases (8%). The primary indications for a third intervention included structural valve deterioration (SVD) (39/51, 76%), non-SVD (8/51, 16%), and endocarditis (2/51, 4%). Excluding patients with a mechanical prosthesis, predictors of SAVR as third intervention included a lower STS score (OR: 0.58; 95% CI: 0.34-0.98; P = 0.04) and the presence of moderate or severe prosthesis-patient mismatch (OR: 44.8; 95% CI: 2.41-122.00; P = 0.01). Thirty-day device success was 85% for TAVR and 94% for SAVR. In the THIRD registry, SVD emerged as the predominant indication for a third aortic valve procedure. The most frequent procedure sequence was SAVR-SAVR-TAVR, whereas TAVR-TAVR-TAVR was less common. Although the short-term outcomes in our selected cohort were favorable, further investigation is needed.

4 March 2021 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
MCMauricio Castillo-Perez
Mauricio Castillo-Perez
CJCarlos Jerjes-Sánchez
Carlos Jerjes-Sánchez
DRDavid Rodríguez
David Rodríguez
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
JPJathniel Panneflek
Jathniel Panneflek
MVMauricio Vazquez-Guajardo
Mauricio Vazquez-Guajardo

1 December 2020 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
HCHector Betancourt-Del Campo
Hector Betancourt-Del Campo
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
MCMauricio Castillo-Perez
Mauricio Castillo-Perez
HGHector López-De la Garza
Hector López-De la Garza
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
MIMarcos Ibarra-Flores
Marcos Ibarra-Flores
Background: From asymptomatic patients to severe acute respiratory distress syndrome, COVID-19 has a wide range of clinical presentations, and venous thromboembolism has emerged as a critical and frequent complication. Case summary: We present a case of a 69-year-old man with a clinical presentation of massive-like pulmonary embolism (PE) overlapping with severe COVID-19 pneumonia. The diagnosis was made based on hypotension, severe oxygen desaturation (33%), and right ventricular dysfunction (RVD). We used alteplase and low-molecular-weight heparin, obtaining immediate clinical improvement. Also, we identified an extremely elevated D-dimer (31.2 mcg/mL), and computed tomography pulmonary angiography (CTPA) revealed an unexpected low thrombus burden and a crazy-paving pattern. Considering this, we decided to discontinue the alteplase. Therefore, the mechanisms of pulmonary hypertension and RVD could be multifactorial. Despite the patient’s respiratory status worsening and ongoing mechanical ventilation, biomarkers kept lowering to normal ranges. It appears a favourable outcome was related to early PE diagnosis and a multimodal therapeutic approach. Discussion: Physicians in the ER should be warned about extremely high D-dimer measurements and severe oxygen desaturation as possible markers of severe COVID-19 pneumonia in patients with high-clinical suspicion of PE. Although ESC guidelines recommend immediate reperfusion in cardiogenic shock secondary to PE, we suggest initial CTPA in patients with high-clinical suspicion of severe COVID-19.

15 December 2021 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
MCMauricio Castillo-Perez
Mauricio Castillo-Perez
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
ACAlejandra Castro-Varela
Alejandra Castro-Varela
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
EVEduardo Vázquez-Garza
Eduardo Vázquez-Garza
JPJathniel Panneflek
Jathniel Panneflek
To our knowledge, the treatment, outcome, clinical presentation, risk stratification of patients with venous thromboembolism and COVID-19 have not been well characterized. We searched for systematic reviews, cohorts, case series, case reports, editor letters, and venous thromboembolism COVID-19 patients’ abstracts following PRISMA and PROSPERO statements. We analyzed therapeutic approaches and clinical outcomes of venous thromboembolism COVID-19 patients. Inclusion: COVID-19 patients with venous thromboembolism confirmed by an imaging method (venous doppler ultrasound, ventilation-perfusion lung scan, computed tomography pulmonary angiogram, pulmonary angiography). We assessed and reported the original Pulmonary Embolism Severity Index for each pulmonary embolism patient. In addition, we defined major bleedings according to the International Society of Thrombosis and Haemostasis criteria. We performed a systematic review from August 9 to August 30, 2020. We collected 1,535 papers from PubMed, Scopus, Web of Science, Wiley, and Opengrey. We extracted data from 89 studies that describe 143 patients. Unfractionated and low-molecular-weight heparin was used as parenteral anticoagulation in 85/143 (59%) cases. The Food and Drug Administration-approved alteplase regimen guided the advanced treatment in 39/143 (27%) patients. The mortality was high (21.6%, CI 95% 15.2-29.3). The incidence of major bleeding complications was 1 (0.9%) in the survival group and 1 (3.2%) in the death group. Pulmonary Embolism Severity Index was class I in 11.6% and II in 22.3% in survivors compared to 0% and 6.5% in non-survivors, respectively. Patients who experienced venous thromboembolism events at home were more likely to live than in-hospital events. We determined a high mortality incidence of pulmonary embolism and a low rate of bleeding. Unfractionated and low-molecular-weight heparin drove parenteral anticoagulation and alteplase the advanced treatment in both groups. The original Pulmonary Embolism Severity Index could be helpful in the risk stratification.

28 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
GTGabriela Tirado-Conte
Gabriela Tirado-Conte
ASAsad Shabbir
Asad Shabbir
MMMatias Mon-Noboa
Matias Mon-Noboa
JCJorge F. Chavez
Jorge F. Chavez
LNLuis Nombela
Luis Nombela
In current clinical practice, commissural alignment of the transcatheter heart valve (THV) during transcatheter aortic valve implantation (TAVI) is seldom achieved. Orientation of the THV within the aortic root and the subsequent influence upon leaflet haemodynamic function, coronary blood flow, and ease of access to the coronary ostia are gaining significant interest. Herein, we review the incidence and clinical implications of commissural misalignment in TAVI and offer thorough descriptions of how optimal alignment can be achieved with several different contemporary THV devices.

3 January 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
GTGabriela Tirado-Conte
Gabriela Tirado-Conte
PJPilar Jiménez-Quevedo
Pilar Jiménez-Quevedo
MMMatías Mon-Noboa
Matías Mon-Noboa
EPEduardo Pozo
Eduardo Pozo
LNLuis Nombela
Luis Nombela